Zevra Therapeutics (ZVRA) Q2 2026 earnings review
MIPLYFFA Scales Rapidly, Driving True Operational Profitability
Zevra's Q2 2026 results mark a definitive turning point for the business. The company shed the noise of prior quarters' one-time asset sales and write-downs to post a clean, highly profitable quarter. Total revenue accelerated 53% YoY to $39.7 million, powered almost entirely by the U.S. commercial execution of MIPLYFFA. Crucially, Zevra demonstrated massive operating leverage: while revenue grew by $13.8 million YoY, operating expenses actually fell by $3.2 million. This jaws effect resulted in an Adjusted Net Income of $15.2 million, definitively proving the underlying business model is cash-generative. With $260.2 million in cash and zero debt, the company is now fully self-funding, though slow pipeline enrollment remains a glaring blind spot.
🐂 Bull Case
MIPLYFFA U.S. net revenue jumped to $30.2M in Q2 (up from $24.6M in Q1), supported by 14 new prescription enrollments. The drug is effectively penetrating the U.S. NPC market with stable 69% covered-lives access.
SG&A expenses dropped from $20.8M a year ago to $16.6M today. Combined with zero debt and $260M in cash, the company has insulated itself from capital market dependency while dropping incremental revenue straight to the bottom line.
🐻 Bear Case
The Phase 3 DiSCOVER trial for Celiprolol (VEDS) is crawling. Despite management's previous focus on acceleration, only 4 patients were added in Q2 (down from 10 in Q1). The event-driven trial only has 3 confirmed events.
Management had to request a 're-examination' of its MAA for arimoclomol in Europe, signaling pushback or delays from the EMA that could bottleneck the next major geographical growth vector.
⚖️ Verdict: 🟢
Bullish. The core commercial story is working better than expected. MIPLYFFA is a cash-printing engine, and management's cost discipline has transformed the company from a cash-burning biotech into a highly profitable commercial operation. Pipeline risks remain, but they are eclipsed by the strength of the U.S. launch.
Key Themes
MIPLYFFA Launch Trajectory is Accelerating
MIPLYFFA remains the undeniable growth engine. Net revenue hit $30.2 million for the quarter, an acceleration from Q1's $24.6 million. The company captured 14 new prescription enrollment forms, bringing the total to 184 since launch. Market access remains locked in at a healthy 69% of covered lives, and a new Orange Book listing through 2041 secures the asset's long-term commercial runway.
Stunning Operating Leverage
The most impressive element of Q2 was Zevra's cost control. Despite total net revenue growing 53% YoY, total operating expenses actually shrank 13% (from $24.2M to $21.0M). SG&A dropped significantly ($16.6M vs $20.8M YoY) due to decreased professional fees and third-party spending. This proves the company has successfully transitioned out of its expensive launch phase and into a highly profitable steady state.
Celiprolol Trial Pace is Decelerating
Management's narrative emphasizes 'operational execution', but the pipeline tells a different story. The Phase 3 DiSCOVER trial for Celiprolol enrolled only 4 patients in Q2, a sharp deceleration from the 10 patients enrolled in Q1. The total stands at 66 patients with only 3 confirmed clinical events. For an event-driven trial requiring 28 events for an interim analysis, this sluggish pace directly contradicts the positive execution narrative and pushes potential pipeline value further into the future.
European MAA Re-examination Signals Delays
Zevra noted it has 'requested a re-examination' of its Marketing Authorisation Application for arimoclomol in the EU. Requests for re-examination typically occur after a negative opinion or significant pushback from the CHMP. This introduces material regulatory risk and likely delays the European commercial launch, which was expected to be the next major revenue driver.
Technological Innovation Validated by Long-Term Data
Zevra's focus on the TFEB and TFE3 transcription factors to upregulate CLEAR genes continues to build clinical validation. The company highlighted new publications in Molecular Genetics and Metabolism Reports showing no new safety signals in pediatric patients and verifying long-term real-world effectiveness. By proving it can safely halt disease progression through this specific lysosomal mechanism, Zevra strengthens its clinical differentiation against any future competitors.
Other KPIs
A massive reversal from an adjusted net loss of $2.4 million in Q2 2025. By backing out non-cash fair value adjustments ($6.4M this quarter) and ignoring the prior year's PRV sale and impairment noise, investors can finally see the true cash-generating power of the MIPLYFFA franchise. Adjusted EPS hit $0.25 per share.
Stable. The Expanded Access Program continues to provide a lucrative and stable revenue floor ($10.2M in Q1, $9.0M in Q2). With 132 patients enrolled globally, it serves as a critical pre-commercialization strategy while EU regulatory battles play out.
Dead. Following the strategic de-emphasis and massive $70M+ impairment last year, OLPRUVA revenue remains immaterial. The company has successfully contained the damage and stopped throwing good money after bad in the mature UCD market.
Guidance
Stable. Management reiterated that its $260.2 million cash balance is enough to execute strategic priorities without raising outside capital. Given the newly demonstrated $15M/quarter adjusted profitability and zero debt, this is a highly credible claim.
Key Questions
European Regulatory Friction
You requested a re-examination of the MAA for arimoclomol. What specific concerns did the CHMP raise regarding the data package, and what is the realistic timeline for an approval decision now?
Celiprolol Bottleneck
Enrollment for the DiSCOVER trial decelerated to just 4 patients this quarter, and we only have 3 confirmed events. How do you plan to un-bottleneck this trial, and does this sluggish pace alter your strategy for upcoming FDA discussions regarding accelerated pathways?
MIPLYFFA Growth Ceiling
With 184 enrollments, you have captured roughly half of the historically diagnosed NPC population. As you exhaust the low-hanging fruit of the known centers of excellence, what are the specific leading indicators showing that your AI and genetic testing initiatives are successfully finding truly undiagnosed patients?